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ABSTRACT
Background A large proportion of the 200 000 HCV-infected individuals in the UK are undiagnosed or lost to follow-up. Engaging known
infected individuals in treatment is essential for elimination.
Methods Using PHE surveillance data and HCV treatment registers from North East of England (NE) treatment centres for 1997–2016, we
estimated the number of HCV cases not linked to treatment and the proportion with active infection. We compared distances of treated and
untreated cases to treatment services, and assessed the effect of expanding HCV treatment into existing drug and alcohol treatment centres in
the NEE on treatment accessibility.
Results The odds of being treated was associated with distance to treatment services. Conﬁrmatory results for ~50% were not reported to
PHE NE. Overall, 3385 patients reported to PHE NE had no record of treatment; we estimated 1621 of these may have been lost to follow-up
after conﬁrmation of active infection.
Conclusions Poor access to healthcare services may contribute to under-diagnosis or loss to follow-up. Expanding HCV treatment delivery into
NEE drug and alcohol treatment centres would improve the accessibility of treatment services to people infected with/at risk of HCV. This may
increase the proportion receiving treatment and support progress towards elimination.
Keywords communicable diseases, geography, secondary and tertiary services
Introduction
Hepatitis C virus infection (HCV) is a major cause of liver-
related morbidity and mortality in the Western world1 and
an important public health burden in the UK, with an esti-
mated 200 000 people living with chronic infection, of
whom a signiﬁcant proportion are undiagnosed.2 Most
HCV infection in the UK is associated with injecting drug
use. Approximately 70% of those infected with HCV
develop chronic infection which is frequently asymptomatic.
Consequently, HCV often remains undiagnosed for many
years after infection and is sometimes only identiﬁed
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following complications related to end stage liver disease.1
Chronic HCV patients are infectious and a potential source
of onward transmission irrespective of symptoms. Untreated
HCV results in persistent hepatitis that progresses to cirrho-
sis in ~20% of cases after 20–30 years.3 HCV may result in
extra-hepatic manifestations, and people with chronic infec-
tion report poorer quality of life compared with the general
population.4,5
Therapeutic advances mean HCV is now eminently treat-
able with >95% of patients achieving sustained virological
response (SVR; persistent clearance of HCV = ‘cure’) fol-
lowing an 8–12-week course of oral direct acting antiviral
(DAA) drugs.6 This provides an unprecedented opportunity
to reduce HCV-associated morbidity and mortality and
ultimately eliminate HCV as a public health threat, identiﬁed
as a World Health Organisation target by 2030.7 Elimination
requires successful treatment of a critical proportion of
infected individuals, alongside implementation of other avail-
able control measures.7 For maximum impact, control and
treatment strategies should focus on populations at highest
risk, which in the UK is people who inject drugs.2
The large proportion of infected individuals unaware of
their HCV status or lost to follow-up (LTFU), limits elimin-
ation efforts.7 The typical treatment journey for HCV is
long and complex,8 with potential for loss to follow-up at all
stages from testing through to treatment completion. In the
UK, those at risk of HCV are diagnosed by detection of
HCV antibody (anti-HCV Ab), alone or in combination with
HCV antigen (HCV Ag). Presence of anti-HCV Ab indicates
current or recovered infection, while HCV Ag and/or RNA
indicate active infection.
To increase treatment coverage and completion rates, the
identiﬁcation and re-engagement of LTFU individuals is a
priority for HCV Operational Delivery Networks (ODNs),
which co-ordinate treatment delivery in England.9 Improved
understanding of the reasons for loss to follow-up is
urgently required to address this problem. Public health sur-
veillance datasets are a resource for the identiﬁcation of pre-
viously diagnosed and notiﬁed cases, of which those with no
corresponding treatment record represent potentially LTFU
cases.
The North East and North Cumbria (NENC) HCV
ODN coordinates HCV treatment in the North East of
England (NEE), delivered through treatment centres in six
acute NHS Trusts. Patients are also treated in prisons and
some drug and alcohol treatment services (DAS). Treatment
of NE patients in health facilities outside of NEE is
uncommon.
We sought to estimate the burden of known active HCV
infection among untreated individuals in NEE using the
PHE NE infectious disease surveillance system (EpiNorth3)
and treatment registers compiled by NHS HCV treatment
centres in NEE. We compared the proximity of existing
treatment services to individuals known and not known to
be treated and estimated the potential effect on treatment
accessibility of expanding treatment delivery into all NEE
DAS.
Methods
This project was registered as a service evaluation project
with the Newcastle upon Tyne Hospitals NHS Foundation
Trust Clinical Governance Department.
Data sources
Surveillance dataset
All HCV infections reported from 1 January 1997 to 31
December 2016 in NEE were identiﬁed from EpiNorth3.
Reported infections included positive screening results for
anti-HCV Ab, and positive results of tests for HCVAg, RNA
and genotype. Each reported infection was linked to its
patient identiﬁer to produce a dataset of patient records.
Individual records were reviewed to identify laboratory con-
ﬁrmed active infection (those with a positive HCV Ag, RNA
or genotype). The remainder had no recorded test to conﬁrm
active infection and hence active infection could not be distin-
guished from spontaneously resolved cases in this group.
Exclusions
Anonymised records, including those referred from sexual
health clinics without patient identiﬁable data were excluded
from further analysis. Non-NEE residents, cases from pris-
ons (as HCV treatment services are currently delivered
within prisons) and those without a valid postcode were
excluded from spatial analysis (see below) after linking.
Treatment datasets
Treatment outcome data was available for patients who
received antiviral treatment for HCV at four of the six NEE
treatment centres: the County Durham and Darlington,
Gateshead Health, South Tees and Newcastle-upon-Tyne
Foundation Trusts, accounting for ~95% of patients treated
in the NEE from 1997 to 2016. Outcomes were categorised
as SVR, failed treatment, LTFU or died.
Record linkage
The surveillance and treatment datasets were linked to cat-
egorise those in the surveillance dataset with active infection
as ‘treated’ or ‘untreated’. Individuals in the surveillance
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dataset matched to cases in the treatment datasets were clas-
siﬁed as having started treatment (‘treated’), and individuals
not matched to cases in the treatment datasets were classi-
ﬁed as not known to be treated (‘untreated’).
A fuzzy matching function was implemented in R10 to
compare each case in the surveillance dataset with each case
in each treatment dataset. This function calculates a similar-
ity score for each potential match based on edit distances
between corresponding ﬁelds. Edit distances can be based
on the minimum number of character transpositions (Jaro–
Winkler distance11) or the minimum number of character
edits (Levenshtein distance12) between ﬁelds, and are
adjusted so a score of zero represents no similarity and a
score of one indicates an exact match. Jaro–Winkler distance
was used to score the similarity of ﬁrst name and surname
ﬁelds; Levenshtein distance was used to compare date of
birth and NHS number. A match in the sex ﬁeld scored one
and a mismatch scored zero. String distance scores for each
ﬁeld were weighted according to the relative discriminatory
power of the ﬁeld: NHS number was considered the most
speciﬁc; followed by surname and date of birth, which were
weighted equally; then by ﬁrst name; and ﬁnally by sex. For
each potential match, the weighted edit distances for each
ﬁeld were summed to derive an overall similarity score, and
adjusted to a percentage.
All comparisons between the two datasets were ranked by
similarity score. Each record from the surveillance dataset
was linked to a single ‘potential match’ in the treatment data-
set which was the record with the highest similarity score. A
cut-off similarity score of 80% was used to deﬁne matches;
potential matches below 80% were examined manually.
Estimating the under-reporting of laboratory
results
Given that all ‘treated’ cases would require laboratory con-
ﬁrmation prior to treatment initiation, matched treated cases
with no recorded conﬁrmatory test in the surveillance data-
set were deﬁned as ‘non-recorded’ conﬁrmations. The ratio
of ‘treated’ cases with ‘non-recorded’ conﬁrmations to those
with a recorded conﬁrmatory result was calculated and
deﬁned as the ‘non-recorded’ ratio. The non-recorded ratio
was applied to the number of ‘untreated’ individuals in the
surveillance dataset without recorded conﬁrmatory tests to
estimate the number of non-matched individuals that were
likely to be HCV conﬁrmed but not recorded as such.
Spatial analysis
Records from the surveillance cohort without a home post-
code recorded were dropped from spatial analysis. Home
postcodes of all remaining individuals were geocoded and
integrated in a geographical information system (ArcGIS
(version 10.3, ESRI Inc., Redlands CA, USA)13) with HCV
treatment service and DAS locations. Those DAS not cur-
rently providing HCV treatment were categorised as alterna-
tive treatment locations. Euclidean (straight-line) distances
from individual home postcodes to current and alternative
treatment locations were calculated.
Average annual rates of ‘treated’ and ‘untreated’ cases
were calculated at ward-level, using 2015 ward-level popula-
tions from the Ofﬁce for National Statistics14 as
denominators.
Statistical analysis
For both ‘treated’ and ‘untreated’ case, Euclidian distance
from home to nearest existing treatment services were used
to investigate the association between proximity of services
and the likelihood of having started treatment. We used the
non-parametric k-sample χ2 test for equal medians, and cal-
culated Fisher’s exact P-value (two-sided) to test the null
hypothesis that the two groups were drawn from popula-
tions with the same median.
We deﬁned two categories of proximity to the nearest
treatment facility, by splitting the group at the median dis-
tance, rounded to the nearest kilometre and used univariate
logistic regression analysis to estimate the effect of distance
on the odds of having started treatment. The effect of dis-
tance (log-transformed) as a continuous predictor was also
tested using logistic regression.
To explore the potential effect of expanding treatment
delivery into all DAS in NEE, we calculated the average per-
centage change in median distance from the ‘untreated’
cases’ home addresses to the nearest treatment centre,
including both alternative and existing treatment locations.
The null hypothesis that including the alternative treatment
locations would not change the median distance to treatment
was assessed with a median test (as above).
All statistical analysis was conducted in STATA 14.15
Results
A total of 4801 reported HCV infections were recorded in the
PHE NEE surveillance dataset over the study period. After
exclusion of anonymised records, 4243 individuals remained in
the surveillance cohort. Over the same period, 1447 patients
were recorded as having received treatment at one of the
NHS-Trusts included in the study. From the surveillance data-
set, 858 (20.2%) were matched to a case with record of treat-
ment (‘treated’), while 3385 records could not be matched
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(‘untreated’). Figure 1 shows reasons why cases were excluded
or not mapped. Proportions of cases in prisons and out-of-
area were similar between the matched and unmatched cases.
The proportion of individuals with invalid or missing post-
codes was higher amongst ‘treated’ cases (4.1 versus 0.9%
missing postcode). Overall, 675 (78.7%) of the ‘treated’ cases
and 2929 (86.5%) ‘untreated’ individuals were mapped.
Of the ‘treated’ individuals in the surveillance dataset, 328
(48.6%) had laboratory evidence of active HCV infection
recorded within EpiNorth3, equating to a ‘non-recorded’
ratio of 1.06. In total, 788 (26.9%) ‘untreated’ individuals
from the surveillance dataset had a conﬁrmatory test result
(indicating active HCV infection) recorded within the
EpiNorth3 during the study period. Applying the ‘non-
recorded’ ratio to this ﬁgure, we estimated ~833 additional
‘untreated’ individuals may have had HCV infection con-
ﬁrmed, but not recorded in EpiNorth3. This represented
1621 cases, out of 3385 ‘untreated’ records, estimated or
known to have conﬁrmed HCV infection.
Figure 2 shows the distribution of rates of hepatitis C
reported in the surveillance dataset from 1997 to 2016; (A)
‘treated’ and (B) ‘untreated’, at ward level, with the locations
of existing treatment services in secondary care treatment
hubs and drug and alcohol treatment centres, and other
drug and alcohol treatment centres into which treatment
delivery could be expanded.
The distributions of linear distances from home postcode
to nearest existing treatment facility were highly positively
skewed for both ‘treated’ and ‘untreated’ cases. The median
distance to the nearest existing treatment facility for the
entire surveillance cohort was 3.93 km: we categorised cases
living within 4 km as ‘close proximity’.
The median distance among ‘treated’ cases was 3.43 km
(interquartile range (IQR): 2.26–10.5 km), and the median
among ‘untreated’ individuals was 4.20 km (IQR:
2.28–9.17 km). The Pearson χ2 statistic for equality of medians
was 5.35, with a Fisher’s exact P-value (two-sided) of 0.02.
Logistic regression analysis showed the odds of being
treated was 1.22 (95% CI: 1.02–1.44) higher among indivi-
duals within close proximity of the nearest existing treatment
facility, compared to those living further away (Table 1).
There was no effect of distance as a continuous predictor.
When all DAS were considered potential treatment deliv-
ery locations, the median distance to the nearest facility
decreased from 3.93 to 1.79 km (IQR: 0.81–3.74 km), repre-
senting a decrease of 57.3%. The Pearson χ2 statistic for the
equality of medians was 446.64, with a Fisher’s exact P-value
(two-sided) of <0.001.
Discussion
Main ﬁndings of this study
We identiﬁed 788 conﬁrmed cases reported to PHE but
with no record of treatment, and signiﬁcant underreporting
of conﬁrmatory test results to PHE: of 858 patients who
were notiﬁed to PHE and started treatment at one of
included the NHS-Trusts over the study period, ~50% had
not been reported as conﬁrmed cases to PHE NE.
Applying this scale of underreporting to the number of con-
ﬁrmed cases with no treatment record, we estimated the
potential burden of diagnosed active HCV cases in the NEE
LTFU prior to treatment initiation to be ~1621 over the
study period, out of 3385 individuals with no record of
treatment.
The remaining 1764 with no treatment record will include
individuals with unreported negative tests, and cases LTFU
before having a test to conﬁrm active HCV infection. Some
of this group will have been treated previously but, because
~70% of those with detected anti-HCV will have chronic
Fig. 1 Inclusion and exclusion of individuals with evidence of past or cur-
rent HCV infection notiﬁed to the PHE NEE 1997–2016, numbers known to
have started treatment in North East Trusts and numbers of conﬁrmed
active infections reported to PHE NEE. 1Cases with positive conﬁrmatory
test results (HCV Ag or RNA detection) recorded in the surveillance system.
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infection if untreated, a large proportion are expected to
have undiagnosed active HCV infection.
We found evidence that ‘treated’ individuals lived closer
to HCV treatment services, compared to those who were
LTFU before treatment initiation or conﬁrmation of infec-
tion. Living within 4 km of a treatment facility was a strong
predictor of having started treatment. Expanding HCV
treatment into DAS in the NEE would signiﬁcantly increase
the geographical accessibility of HCV treatment services to
untreated individuals.
What is already known on this topic
HCV is known to be grossly under-diagnosed worldwide
and in the UK,1,2 although the scale of this problem is
unknown. The geographical accessibility of health services is
associated with uptake of various healthcare services in the
UK and other high-income settings.16–18 A study of HCV
patients in Tayside, Scotland, found those living further
from a specialist centre were less likely to be referred for
treatment (although not more likely to be LTFU after refer-
ral).19 HCV patients tend to be among the most deprived
population sectors in the UK,20 thus, the personal costs of
treatment completion may be felt particularly strongly by
this group.
HCV patients favour outreach clinics over the hospital
setting, concordance with treatment being higher in those
treated in DAS.21
What this study adds
The evidence of the association between the distance to
HCV treatment services and potential loss to follow-up has
important implications for the strategic development of
HCV services. The maps presented here have facilitated the
strategic expansion of HCV treatment outreach services by
Fig. 2 The average annual rate of hepatitis C reported to PHE NEE 1997–2016 and (A) who started treatment and (B) with no record of treatment, at ward
level. *Number of cases per 100 000 population per year (population ﬁgures from ONS for 2015).
Table 1 Univariate logistic regression analysis of the effect of distance to
the nearest HCV treatment service on the odds of being treated for HCV,
in individuals with evidence of current or past HCV infection.
Predictor OR of being treatedb Std. Err. P > z 95% CI
>4 kma 1
<4 kma 1.22 0.11 0.03 1.02–1.44
Constant 0.24 0.02 0 0.21–0.27
OR = odds ratio.
aDistance to the nearest facility offering HCV treatment.
bDeﬁned by record of treatment for HCV in one of the North East Trusts.
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the NENC HCV ODN, prioritising areas with higher rates
of untreated HCV. At the time of writing, the number of
NEE outreach clinics has increased to 17, which has helped
signiﬁcantly increase treatment rates to >600/year in 2017/
18. Further expansion of outreach services using the maps
to identify viable treatment locations is planned.
Integrating HCV treatment with DAS in a holistic
approach to managing addiction is likely to improve treat-
ment uptake by targeting this particularly vulnerable group
who are at highest risk of HCV infection. If HCV treatment
services were expanded into all NEE DAS, more than 75%
of ‘untreated’ individuals would live within close proximity
of a treatment location. Delivery of HCV treatment from
general practitioners’ surgeries would also increase proximity
of patients to treatment services. If proximity is a driver of
LTFU, such service reorganisation could signiﬁcantly reduce
loss to follow-up.
The results of this exercise are also being used to re-
engage potential LTFU cases in treatment or conﬁrmatory
testing: patients identiﬁed in this study as untreated or with
unknown HCV status are being followed-up by Hepatology
Assistants within the NENC HCV ODN. This is in line
with recommendations from a recent All-Party
Parliamentary Group on ‘Eliminating Hepatitis C in
England’,22 advising that PHE provide ODNs with data on
known untreated HCV cases, so these individuals can be
contacted to engage them in treatment. Targeting of testing
to individuals without laboratory conﬁrmation is expected to
be a cost-effective approach to increasing treatment cover-
age, compared to a less targeted approach, which would
result in re-testing of individuals who may already be known
to have active HCV.
This work has illustrated the scale of underreporting of
conﬁrmatory results for HCV tests to PHE. Improving the
reporting of HCV conﬁrmatory testing is vital to ensure that
surveillance data gives a more accurate account of HCV
infection rates in the community, and is of maximum value
to supporting healthcare and public health action. This exer-
cise could be repeated in other regions through collaboration
between PHE and HCV ODNs, which each maintain
equivalent datasets to those in the NEE. This would provide
a nation-wide estimate of the potential burden of known
active, untreated HCV infection, and possible cases LTFU
before conﬁrmation.
Limitations of this study
This study is subject to some limitations related to linking
routine datasets. The group we deﬁned as ‘untreated’ is likely
to contain some cases who had been treated, for example
through another NHS-Trust, or under a different name. The
scale of this misclassiﬁcation is not possible to estimate
without further data collection, but its potential impact could
make the two analysis groups more similar: potentially
resulting in an underestimate of the difference in proximity
of treatment services between the two groups.
Around 12% of records from the surveillance database
were anonymised, largely due to reporting of the infection
from sexual health clinics. A proportion of this group is
expected to be treated. These cases were excluded from the
analysis, so anonymisation would have had little impact on
the spatial analysis results, if the distributions of distances to
treatment services among treated and non-treated cases are
assumed to be equivalent among anonymous and identiﬁ-
able cases.
Some cases could not be mapped as their home post-
codes were not available. However, this information was
assumed to be missing at random and thus unlikely to affect
the spatial analysis results. In addition, linear distance does
not give a direct indication of time or monetary costs of
accessing healthcare. However, we believe this measure to
be a good indicator of accessibility as it has been shown to
correlate closely with drive-time in the UK.23,24 We used a
cut-off of 4 km to divide the cases into two approximately
equal-sized groups with higher and lower levels of access to
treatment. Although this categorisation is relatively crude, a
4 km radius has previously been used to deﬁne populations
with better and worse access to health facilities in the
UK,18,25 with evidence that the latter group show lower
attendance rates at general practitioners’ clinics.18 Further
analysis would be required to validate the relationship
between treatment proximity and access rates in this speciﬁc
context, and to assess the true impact of interventions to
reduce proximity on treatment completion rates.
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